Ipsen SA to Discuss the ELATIVE Phase III Trial Results Call Transcript
Hello, and welcome to Ipsen's Investor Science call at AASLD. I'd now like to turn over to Craig Marks of Ipsen.
Hello, everyone. As you just heard, I'm Craig Marks, Vice President of Investor Relations at Ipsen. We're live in Boston, and it's a real pleasure to welcome you at Ipsen's Investor Science Conference Call here at the 2023 AASLD meeting. The plan for this call is to focus on the results from the elafibranor ELATIVE Phase III trial presented yesterday at the late-breaker session.
We plan to comment today only on the results of the trial. Commercial questions will be answered at next month's Capital Markets Day.
Next slide, please. This is our usual safe harbor statement. Next slide, please. I'd now like to introduce you to our 3 speakers today. Jennifer Schranz, Global Head of Rare Disease R&D, Ipsen will summarize our focus in rare disease and our extensive presence at AASLD over the past few days. Dr. Christopher Bowlus, Professor and Chief of the Division of Gastroenterology and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
